Build a reference frame, save a practice trade, or preview a draft. No brokerage order is placed.
Paper trade unavailable: missing risk-bounded frame
Reference only. Not financial advice. No brokerage order is placed.
Why $BMY?
BMY18WATCHpharma
Quantitative
Convergence score: 18 (12 signals firing YoY)
Catalysts
Clinical trial milestone: A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT)
Clinical trial milestone: A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
Tickers Catalyst Edge tracks as moving with this name. Cross-correlation derived from sector + score-cohort proximity.
Earnings Catalyst
No recent earnings event.
Auto-generated from public filings + tier-1 wires. Catalyst Edge publishes its picks and its losses — see the trust report and methodology.
Not financial advice. Confirm independently before trading.
You came here for BMY. You found it after it moved, the same way everyone else did.
$99 once — every ticker on this site ranked before the open.
Tier 1 setups touched +2% intraday 49.5% of the time across 329 tracked calls. Baseline for everything else: 40.8%. That is a +8.7 point edge, measured from the NEXT OPEN — the first price you could actually pay, not the prior close. We publish the misses too: https://catalystedgescanner.com/trust/
Click Become a Founding Member below.
Pay $99 once — not monthly, not ever again.
You keep every future release at that price. Tomorrow's ranked list
lands at 3:30 AM ET, before the open.
29 of 30 founding seats left. The price goes up when they are gone.